Lite Strategy, Inc.

LITS Healthcare Biotechnology

Lite Strategy, Inc.’s revenue for fiscal 2024 (year ended June 2024) was $65.3 million, up 33.8% from fiscal 2023. In the quarter to June 2026, EPS fell 11.0% and free cash flow grew 179.3%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

1.14 0.06 −5.00%
Market cap
$36.3M
P/E
0.0×
Fwd P/E
−0.5×
Dividend yield
—
F-score
5/9
Altman Z
−8.07
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
12.39 10.04 11.53 5.74
Net Debt/EBITDA
2.70 0.29 0.35 0.50
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(3.55) (0.05) 0.01 0.06
Book value per Share
3.81 2.19 1.59 1.20
Free Cash Flow
(104.51) (1.93) 0.41 1.95
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates · fundamentals updated 30 Sep 2026